In this regard, it is noteworthy that a selective glucagon receptor antagonist increased hepatic fat in patients with T2D 23
(3) Peroni CN, Hayashida CY, Nascimento N, Longuini VC, Toledo RA, Bartolini P, Bowers CY, Toledo SP
This is achieved by virtue of their metabolic effects and reduction of body weight through their central actions of increased satiety and reduced food intake (see Figure 1), thus rendering them highly effective therapies
*Correspondence: Tulika Arora, [email protected] This article was submitted to Gut Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers